About: Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells
Creator	Liu, Ming-Tsan Sung, Wang-Chou Chen, Pin-Wen Chen, Po-Ling Chou, Hsin-I Lai, Chia-Chun Lee, Min-Shi Lu, Chia-Chun Tsai, Shin-Yi Tzeng, Tsai-Teng Weng, Tsai-Chuan Hu, Yung-Chih
source	PMC
abstract	BACKGROUND: Influenza vaccine manufacturers traditionally use egg-derived candidate vaccine viruses (CVVs) to produce high-yield influenza viruses for seasonal or pandemic vaccines; however, these egg-derived CVVs need an adaptation process for the virus to grow in mammalian cells. The low yields of cell-based manufacturing systems using egg-derived CVVs remain an unsolved issue. This study aimed to develop high-growth cell-derived CVVs for MDCK cell-based vaccine manufacturing platforms. METHODS: Four H7N9 CVVs were generated in characterized Vero and adherent MDCK (aMDCK) cells. Furthermore, reassortant viruses were amplified in adherent MDCK (aMDCK) cells with certification, and their growth characteristics were detected in aMDCK cells and new suspension MDCK (sMDCK) cells. Finally, the plaque-forming ability, biosafety, and immunogenicity of H7N9 reassortant viruses were evaluated. RESULTS: The HA titers of these CVVs produced in proprietary suspension MDCK (sMDCK) cells and chicken embryos were 2- to 8-fold higher than those in aMDCK cells. All H7N9 CVVs showed attenuated characteristics by trypsin-dependent plaque assay and chicken embryo lethality test. The alum-adjuvanted NHRI-RG5 (derived from the fifth wave H7N9 virus A/Guangdong/SP440/2017) vaccine had the highest immunogenicity and cross-reactivity among the four H7N9 CVVs. Finally, we found that AddaVax adjuvant improved the cross-reactivity of low pathogenic H7N9 virus against highly pathogenic H7N9 viruses. CONCLUSIONS: Our study indicates that cell-derived H7N9 CVVs possessed high growth rate in new sMDCK cells and low pathogenicity in chicken embryo, and that CVVs generated by this platform are also suitable for both cell- and egg-based prepandemic vaccine production.
has issue date	2020-04-02(xsd:dateTime)
bibo:doi	10.1186/s12929-020-00645-y
bibo:pmid	32241276
has license	cc-by
sha1sum (hex)	13173ec2d584121d2419ad008e5cd6d04f76912a
schema:url	https://doi.org/10.1186/s12929-020-00645-y
resource representing a document's title	Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells
has PubMed Central identifier	PMC7115086
has PubMed identifier	32241276
schema:publication	J Biomed Sci
resource representing a document's body	covid:13173ec2d584121d2419ad008e5cd6d04f76912a#body_text
is schema:about of	named entity 'CVVs' named entity 'Vero' named entity 'develop' named entity 'CVVs' named entity 'yields' named entity 'cells' named entity 'CERTIFICATION' named entity 'REASSORTANT VIRUSES' named entity 'MDCK CELL' named entity 'VACCINES' named entity 'IMMUNOGENICITY' named entity 'viruses' named entity 'CVVs' named entity 'influenza' named entity 'candidate' named entity 'influenza' named entity 'suspension' named entity 'reassortant' named entity 'Vero' named entity 'reassortant' named entity 'Influenza vaccine' named entity 'viruses' named entity 'viruses' named entity 'viruses' named entity 'vaccines' named entity 'H7N9' named entity 'MDCK' named entity 'vaccine' named entity 'viruses' named entity 'certification' named entity 'vaccine' named entity 'CVVs' named entity 'vaccine' named entity 'adjuvanted' named entity 'CVVs' named entity 'H7N9' named entity 'H7N9' named entity 'H7N9' named entity 'CVVs' named entity 'homologous' named entity 'infection' named entity 'H7N9' named entity 'Vero cells' named entity 'influenza vaccines' named entity 'CVVs' named entity 'MDCK' named entity 'Antigen' named entity 'NHRI' named entity 'glutamine' named entity 'adjuvant' named entity 'NHRI' named entity 'influenza' named entity 'H7N9' named entity 'CVVs' named entity 'wild-type' named entity 'CVVs' named entity 'NHRI' named entity 'N-linked glycosylation' named entity 'mutation' named entity 'reassortant' named entity 'neuraminidase' named entity 'CVVs' named entity 'protein' named entity 'Viral titers' named entity 'NHRI' named entity 'pandemic influenza' named entity 'tangential flow filtration' named entity 'antigenic' named entity 'NHRI' named entity 'influenza'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software